Skip to content

Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings

November 12, 2026 · 5 min

Show notes

Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial, presented at the American Heart Association's Scientific Sessions 2026 and published in The Lancet on November 9, 2026. The cardiovascular safety trial enrolled 5,530 adults with overweight or obesity and heart disease, chronic kidney disease, or at least two weight-related risk factors. The main combined endpoint (cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularization or heart failure event) occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89, 95% CI 0.67 to 1.18), meeting the goal of showing no increase in risk; the trial was not designed to show a heart benefit. Under the supplementary estimand at 72 weeks, weight fell by up to 13.7% versus 2.0% with placebo, systolic blood pressure by up to 6.68 versus 1.76 mmHg, and waist size by up to 11.96 versus 2.74 cm. Nausea and vomiting were far more common on survodutide, and 19.3% and 20.8% of people in the two survodutide arms stopped treatment because of gastrointestinal side effects, versus 1.9% on placebo; serious adverse events were similar across groups. Survodutide is not approved anywhere. Boehringer, which funded the trial, says it is moving toward regulatory submissions in obesity and told Fierce Biotech it aims to file for weight loss in the next year.

Sources

  • Boehringer Ingelheim press release (Nov 9, 2026), survodutide SYNCHRONIZE-CVOT results: globenewswire.com
  • The Lancet (Nov 9, 2026), Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov, NCT06077864 (SYNCHRONIZE-CVOT): clinicaltrials.gov
  • Fierce Biotech (Nov 9, 2026), AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test: fiercebiotech.com
  • AJMC (Nov 9, 2026), Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT: ajmc.com

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

All episodes of GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.